Skip to main content
. 2021 May 25;36(5):2818–2826. doi: 10.1007/s00464-021-08570-3

Table 2.

Indications and perioperative outcomes by time periods

Variable Early Period
1998 to 2004
n = 62
Middle Period
2005 to 2011
n = 367
Recent Period
2012 to 2018
n = 803
p value
Indications, n
 CRLM 45 (72.6%) 251 (68.4%) 546 (68%) 0.759
 Primary liver cancera 1 (1.6%) 20 (5.4%) 87 (10.8%) 0.002
 Benign lesions 10 (16%) 35 (9.5%) 77 (9.6%) 0.258
Age, media (IQR) 59 (54–70) 65 (56–73) 66 (56–73) 0.026
Male sex, n 32 (50%) 190 (51.7%) 429 (53.4%) 0.854
ASA score, median (IQR) 2 (2–3) 2 (2–3) 2 (2–3) 0.482
BMI, kg/m2, median (IQR) 24.4 (22.5–27.8) 25 (22.7–28.1) 25.2 (22.7–28.4) 0.998
Resection of multiple (> 1) lesions, n 11 (22.4%) 88 (26.6%) 252 (31.4%) 0.071
Operation time, min, median (IQR) 182 (138–245) 135 (90–200) 120 (81–180)  < 0.001
Blood loss, ml, median (IQR) 550 (200–1225) 250 (50–638) 200 (50–600) 0.023
Concomitant RF or Cryo-ablation, n 6 (9.7%) 18 (4.9%) 50 (6.2%) 0.284
Conversions, n
 Laparotomy 5 (8%) 7 (2%) 28 (3.4%) 0.034
 Hand- Assisted 0 (0%) 7 (1.9%) 14 (1.7%) 0.639
Extent of resection  < 0.001
 Minor 49 (79%) 228 (62%) 422 (52.6%)
  Left lateral sectionectomy 14 40 84
  Resection in AL segments 35 188 338
 Anatomically Major 1 (1.6%) 11 (3%) 71 (8.8%)
  Left hemihepatectomy 1 2 30
  Right hemihepatectomy 0 9 41
 Technically Major 12 (19.4%) 128 (35%) 310 (38.6%)
Total morbidity, n 10 (16.1%) 70 (19%) 170 (21.2%) 0.581
 Grade ≥ II, n 9 (14%) 53 (14.4%) 163 (20.3) 0.038
 Severe (Grade ≥ III), n 4 (6.5%) 28 (7.6%) 95 (11.8%) 0.052
Readmission, n 3 (4.7%) 15 (4.1%) 64 (7.9%)  < 0.001
30-days mortality, n 0 (0%) 1 (0.3%) 3 (0.4%) 1.00
Post op. stay, days, median (IQR) 3 (3–4) 3 (2–5) 2 (2–3)  < 0.001
Median size of tumor, mm (IQR) 30 (24–40) 21 (15–35) 25 (15–40) 0.010
Large tumors (> 50 mm), n 9 (14.5%) 37 (10.1%) 129 (16.1%) 0.024
Median resection margin, mm (IQR) 5 (1–10) 3 (1–8) 3 (1–7) 0.040
Median weight of specimen, g (IQR) 92 (45–159) 51 (24–147) 60 (24–189) 0.153

CRLM colorectal liver metastasis, IQR interquartile range, RF radiofrequency, AL anterolateral

aHepatocellular carcinoma and Intrahepatic Cholangiocarcinoma